drugset

drugset / Trial / NCT05791318

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants

NCT05791318 ↗

Phase 1 Completed 30 enrolled Invivyd, Inc. Novotech (Australia) Pty Limited · collab

RandomizedSequentialQuadruple-blindOther

Summary

A study to investigate the safety, tolerability, and pharmacokinetics of the monoclonal antibody VYD222 in healthy adult participants.

Timeline

Start: 2023-03-28
Primary completion: 2024-05-08
Completion: 2024-05-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VYD222	Monoclonal antibody	—	—

Indications